With two tech-fueled market sell-offs occurring within the last month, volatility (^VIX) can be a concern for many investors who are hoping for stability in their portfolios.

Amplify ETFs Founder and CEO Christian Magoon joins Wealth! to give insight into which ETFs can help during times of volatility.

Magoon advises clients to re-examine "core equity positions" in "this volatile period in the fall." September is historically a tough month for both equity markets (^DJI, ^IXIC, ^GSPC) and bitcoin (BTC-USD) in the crypto space.

"And instead of maybe going just 100% long, looking at a high-quality covered call equity strategy, that would give you kind of the benefit of higher quality names, but then also the ability to have covered call income from those names," Magoon says, "which acts as a hedge during kind of downward market environments, and also kind of benefits in terms of more option income as markets become more volatile."

Magoon elaborates on a potential avenue for investors looking to hop on to the weight-loss drug craze: "We launched the first ETF that tracks this GLP-1 weight loss drug category. That's the Amplify drug Weight Loss Drug and Treatment ETF (THNR)... So it's... the only index based ETF to track this segment that owns the companies that are manufacturing GLP-1s and that are in clinical trials on the GLP-1 side. In addition, it owns some of the enablers of this technology. The companies that are making the injection pens, doing the testing, or third party manufacturing of the drug."

For more expert insight and the latest market action, click here to watch this full episode of Wealth!

This post was written by Nicholas Jacobino